Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to -$32.7 billion.

  • Gsk's Total Non-Current Liabilities fell 883.69% to -$32.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.7 billion, marking a year-over-year decrease of 883.69%. This contributed to the annual value of -$31.5 billion for FY2024, which is 20088.14% down from last year.
  • As of Q3 2025, Gsk's Total Non-Current Liabilities stood at -$32.7 billion, which was down 883.69% from -$32.7 billion recorded in Q2 2025.
  • Gsk's Total Non-Current Liabilities' 5-year high stood at $46.0 billion during Q4 2021, with a 5-year trough of -$50.7 billion in Q1 2021.
  • Over the past 5 years, Gsk's median Total Non-Current Liabilities value was -$32.3 billion (recorded in 2023), while the average stood at -$23.5 billion.
  • In the last 5 years, Gsk's Total Non-Current Liabilities skyrocketed by 6522.7% in 2022 and then plummeted by 20151.19% in 2024.
  • Over the past 5 years, Gsk's Total Non-Current Liabilities (Quarter) stood at $46.0 billion in 2021, then crashed by 30.47% to $32.0 billion in 2022, then fell by 2.33% to $31.2 billion in 2023, then plummeted by 201.51% to -$31.7 billion in 2024, then decreased by 3.29% to -$32.7 billion in 2025.
  • Its last three reported values are -$32.7 billion in Q3 2025, -$32.7 billion for Q2 2025, and -$33.0 billion during Q1 2025.